Living up to its name, C4 Therapeutics Inc. exploded onto the scene before the J.P Morgan Healthcare conference in 2016 with a $73 million series A and a Roche Holding AG deal worth more than $750 million in hand. (See BioWorld Today, Jan. 7, 2016.)